Identification of genetic alterations in Metastatic Castration Resistant Prostate Cancer (mCRPC) may provide scientists and clinicians with a list of new targets for drug research and development. Recently published in Cell, Robinson et al. present the first look at genetic data from mCRPC lesions gathered over multiple years and from many institutions.
Keywords: Actionable tumors; PTEN; androgen deprivation; androgen receptor; genetic alterations; mCRPC; translational medication.